Circadian dysfunction in P23H rhodopsin transgenic rats: effects of exogenous melatonin.
This study focuses on the effects of retinal degeneration on the circadian patterns of P23H rats, as well as on the effect of exogenous melatonin administration. To this end, the body temperature of P23H and Sprague-Dawley rats was continuously monitored and their retinas examined at different stages of degeneration, by means of histological labeling and electroretinogram recordings. Melatonin (2 mg/kg BW/day) was supplied ad libitum throughout the experiment to a subset of animals. The body temperature recordings from wild-type and mutant animals showed no differences in the periodogram and the pattern of the mean waveform. However, a progressive decrease in the relative amplitude of the rhythm (RA), a decline in the coupling strength of the rhythm to environmental zeitgebers (interdaily stability, IS) and increased rhythm fragmentation (intradaily variability, IV) were observed in P23H rats, when compared to wild-type animals. The P23H animals showed a progressive decrease in light-induced retinal responses until reaching 18 months of age. By this age, all photoreceptors had already disappeared, and no responses were found in the EGRs. Exogenous administration of melatonin improved the visual response of P23H rats. In fact, the maximum b-wave recorded at 14 months of age was significantly higher in melatonin-treated P23H rats than in the control animals. Furthermore, the maximum b-wave recorded for P23H rats at the age of 14 months significantly correlated with RA, IS, and IV. This leads us to conclude that vision loss in P23H rats is correlated with a progressive fragmentation of their circadian patterns. Both effects are partially reversed by melatonin administration.
Department of Physiology, Genetics and Microbiology, University of Alicante, San Vicente del Raspeig, Spain. pedro.lax@ua.es
Pedro
P
Lax
Beatriz Baño
BB
Otalora
Gema
G
Esquiva
María de Los Ángeles
Mde L
Rol
Juan Antonio
JA
Madrid
Nicolás
N
Cuenca
D000818:Animals; D030801:Animals, Genetically Modified; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001831:Body Temperature / Q000187:drug effects; D002940:Circadian Rhythm / Q000187:drug effects*; D004596:Electroretinography; D008297:Male; D008550:Melatonin / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D012162:Retinal Degeneration / Q000188:drug therapy / Q000378:metabolism; D012243:Rhodopsin / Q000378:metabolism*
D000975:Antioxidants; D012243:Rhodopsin; D008550:Melatonin